This trial is evaluating whether Treatment will improve 1 primary outcome and 6 secondary outcomes in patients with Patient and Family Engagement. Measurement will happen over the course of Through 7 days after the ICU procedure.
This trial requires 120 total participants across 2 different treatment groups
This trial involves 2 different treatments. Treatment is the primary treatment being studied. Participants will all receive the same treatment. Some patients will receive a placebo treatment. The treatments being tested are not being studied for commercial purposes.
We believe many people do not recognize or engage adequately with the health team, including the patient and family. We provide a brief conceptual framework that might help health providers to think about the relationship with patients and families more systematically including the impact on patients' and families' experiences, perceptions, knowledge and views and the ways that these affect the ability of health professionals and institutions to deliver effective, empathetic and client-centered care.
There is a lack of data in the clinical trials on patient and family engagement. Recommendations for improving the quality of clinical trials in this area include providing information that allows patients to make informed choices of trial interventions, engaging patients and their families to assist in this decision-making process, providing tools to assist patients and families to make informed choices of trial interventions, and optimizing clinical trial design such that studies allow a more informed consumer of the outcomes and potential benefits of trial treatments.
In our experience, the most salient factors of poor engagement with the medical care are lack of patient-specific information-giving systems, lack of consultation time, and lack of continuity of care. We believe patient and family engagement in clinical trials can be improved with the use of tools such as a comprehensive and easily accessible medical record with patient-centric information-giving and consultation times, information about drug/therapy options, and options for communication with clinical trial staff.
If clinicians are to deliver their best patient-centred outcomes, they need to focus on patients and families to ensure that everyone's needs are met and family members' needs are considered.
The signs are as follows: engagement with clinical team, engagement with treatment processes, family involvement with clinical care, patient and family engagement with professional services and patient and family engagement in follow-ups.
Despite the growing body of evidence suggesting that the quality of healthcare and patient and family engagement are highly interdependent, the national performance of measures to monitor and inform clinicians and patients about family engagement remains poor.
The treatment for childhood cancer in Canada depends on factors that vary between patients, families, and institutions. Most children are treated in pediatric oncology departments and at PICUs. Children and families are involved in treatment decision making from a young age.
The recent advancements or developments in therapeutic strategies have allowed for the treatment of this disease in the last 2 decades. Although treatment remains controversial because it is only supported by prospective studies, we [have demonstrated that new treatment regimens may prolong OS in high-risk stage IIIA patients. The new treatment regimen is composed of new therapeutic strategies added with surgery that can achieve more efficient resection, which leads to better prognosis and better OS, as well as chemotherapy.
If a patient or caregiver wishes to engage in a clinical trial, but does not know if their wishes are in keeping with the study protocol, they need to be informed of their possibilities. A well-informed patient may make an informed decision and be better able to participate. A patient, however, does not necessarily want to participate if they are unhappy, feel that the trial is a risk to their well-being, feel that the trial is too burdensome, or feel too uncomfortable with being in the hospital. The burden/stress imposed upon the patient should help the doctor gauge their interest and determine the likelihood of their engagement in the trial.
Having an active family role in care was linked to greater satisfaction with care. This relationship was particularly salient for parents of young or frail adults. This suggests the importance of family involvement, in the context of enhanced primary care, for improving the health outcomes for individuals and their families.
Most side effects are not specific to cannabidiol, except for sleep. Symptoms worsened with long-term use. The most common side effects when not taking cannabidiol are: agitation/aggression; headache; constipation; and dizziness. Side effects were generally milder when using a CBD-containing preparation than when using the CBD/THC preparation, except for sleep, which was mildly more severe with THM/CBD than with THC.
The most salient findings for recruiting patients and families into clinical trials were that trials should: (1) provide adequate family education and support by the trial team (2) empower the patient/family and make them more positive about the trial (3) emphasize the patient's and family's role in treatment decision making. The most common barriers to patient and family involvement were that trials do not provide sufficient incentives and barriers to participation. Overall, a concerted effort from all parties is needed to make clinical trial participation more available to patients and families.